摘要
目的:探讨复方胚肝铁铵片联合蛋白琥珀酸铁治疗妊娠期缺铁性贫血(IDA)患者的临床疗效.方法:选取本院 2020 年 9 月至 2022 年 12 月收治的92 例IDA患者为研究对象,按治疗方案将其分为观察组(n=46,采用复方胚肝铁铵片联合蛋白琥珀酸铁治疗)和对照组(n=46,仅采用蛋白琥珀酸铁治疗).比较两组患者临床总疗效、贫血相关指标[血红蛋白(Hb)、红细胞平均体积(MCV)、红细胞计数(RBC)]、铁代谢指标[血清铁(SI)、膜铁转运蛋白 1(FPN1)、血清铁蛋白(SF)、铁调素-25(Hepcidin-25)]、免疫功能指标(CD3+、CD4+、CD4+/CD8+)、不良反应发生率.结果:观察组患者治疗总有效率(97.83%,45/46)显著高于对照组(82.61%,38/46),差异有统计学意义(P＜0.05);治疗后,观察组患者Hb、MCV、RBC水平均高于对照组,观察组患者SI、SF、Hepcidin-25 水平高于对照组,FPN1 水平低于对照组,差异均有统计学意义(P＜0.05);治疗后观察组患者CD3+、CD4+、CD4+/CD8+水平均高于对照组,差异均有统计学意义(P＜0.05);观察组不良反应总发生率(10.87%,5/46)与对照组(4.35%,2/46)比较,差异无统计学意义(P＞0.05).结论:复方胚肝铁铵片联合蛋白琥珀酸铁治疗IDA患者疗效确切,有助于改善IDA患者贫血症状及铁代谢水平,提高其免疫功能,且安全性高.
Abstract
Objective:To analyze the therapeutic effect of compound iron ammonium succinate tablets combined with iron succinate protein on patients with iron deficiency anemia(IDA)in pregnant women.Methods:A total of 92 patients with IDA admitted to our hospital from September 2020 to December 2022 were selected as research subjects.They were divided into observation group(n=46,received compound iron ammonium tablets combined with oral iron succinate treatment)and control group(n=46,received oral iron succinate treatment).The clinical efficacy of the two groups was compared,as well as the anemia-related indicators[hemoglobin(Hb),mean corpuscular volume(MCV),red blood cell count(RBC)],iron metabolism indicators[serum iron(SI),membrane iron transporter 1(FPN1),serum ferritin(SF),hepcidin-25],immune function indicators(CD3+,CD4+,CD4+/CD8+),and the incidence of adverse reactions in the two groups.Results:The total clinical efficacy rate in observation group(97.83%,45/46)was higher than that in control group(82.61%,38/46),and the difference was statistically significant(P＜0.05).After treatment,the levels of Hb,MCV,and RBC in observation group were higher than those in control group,the levels of SI,SF,and Hepcidin-25 in observation group were higher than those in control group,while the level of FPN1 was lower than that in control group,and the differences were statistically significant(P＜0.05).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+in observation group were higher than those in control group,and the differences were statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reactions between observation group(10.87%,5/46)and control group(4.35%,2/46)(P＞0.05).Conclusion:The efficacy of compound iron ammonium tablets combined with iron succinate protein in the treatment of IDA is confirmed,which helps improve the patient's anemia symptoms and iron metabolism levels,enhance their immune function,and is highly safe.
NETL
NSTL
万方数据